相关实验视频

Updated: Sep 12, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

结合MEK和PARP抑制可以增强直肠癌的辐射反应

Qiyun Xiao¹, Julian E Riedesser², Theresa Mulholland²

¹Department of Medicine II, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University, Research Unit of Precision Diagnosis and Treatment for Gastrointestinal Cancer, Chinese Academy of Medical Sciences, Guangzhou, China; Molecular Medicine Partnership Unit, European Molecular Biology Laboratory, Heidelberg, Germany.

Cell reports. Medicine

|August 9, 2025

概括

研究人员确定了新的药物组合,以加强直肠癌治疗. 以MEK抑制剂和多ADP-核糖聚合酶 (PARP) 抑制剂为向鼠肉瘤病毒/mitogen-activated protein kinase (RAS-MAPK) 信号,与辐射一起显示出作为化学辐射的更少毒性替代品的希望.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药物发现药物发现药物发现

背景情况:

结直肠癌通常在局部晚期呈现,需要新辅助化学辐射.
目前的治疗强化策略增加了毒性.
需要新的治疗方法来改善直肠癌患者的治疗结果.

研究的目的:

发现局部晚期直肠癌的替代治疗策略.
为了确定药物-辐射组合,增强辐射敏感性.
探索新的治疗组合作为替代新辅助化学辐射的替代方案.

主要方法:

建立患者衍生的直肠癌器官体,反映出临床辐射敏感性.
使用这些有机体检查了1596种药物辐射组合.
在细胞系和老鼠异种移植模型中验证有前途的药物组合.

主要成果:

inhibitors of rat sarcoma virus/mitogen-activated protein kinase (RAS-MAPK) 信号传递的抑制剂,特别是 mitogen-activated protein kinase kinase (MEK) 抑制剂,显著增强了对辐射的反应.
MEK 抑制剂抑制了辐射诱导的 RAS-MAPK 激活,并降低了 DNA 修复蛋白 RAD51 的调节.
结合的多ADP-ribose聚合酶 (PARP) 和MEK抑制进一步改善了结直肠癌模型中的放射敏感性.

结论:

MEK 抑制剂代表了一种有前途的策略,以增强直肠癌的放射治疗.
结合MEK和PARP与辐射的抑制,为目前的化学辐射协议提供了潜在的替代方案.
临床试验是有必要的,以评估MEK和PARP联合疗法与辐射在局部发达的直肠癌.

关键词:

修复DNA的修复DNA的修复这是一种MEK抑制剂.这是一种PARP抑制剂.在RAD51中使用RAD51.在 RAS 信号传输中.药物组合查药物组合查有机生物有机物辐射治疗疗法辐射治疗疗法无线电感应器 (Radiosensitizer) 是一种具有无线电感应力的装置.这是直肠癌.

更多相关视频

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...